Loading…
Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.
Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.
Has no approved product and so no sales; trial spending is funded by raising money from investors and from cash on hand. Any future income depends on regulators approving one of its medicines, which would then be sold to a small group of specialist doctors.
Moat: none (IP / patents). Clinical-stage biotech with novel muscle-targeted mechanisms but no approved products yet.
Headquarters: Boulder, Colorado, US · Founded: 2017 · Employees: 146
Size Edgewise Therapeutics (EWTX) is a United States Health Care company (Biotechnology) with a market value of $4.89B, the 1195th largest of 3,117 United States companies the cockpit tracks. Shares closed at $45.04 on 6 Nov 2026.
Performance Over six months the shares gained 27.5%, against -1.2% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Short interest Short interest is 10.8% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.33M | -$2.27M | -$2.29M | -$1.73M | -$538,000 |
| EBITDA | -$217M | -$189M | -$157M | -$113M | -$71.1M |
| Net income | -$197M | -$168M | -$134M | -$100M | -$67.6M |
| Free cash flow | -$159M | -$144M | -$110M | -$97.7M | -$58.2M |
| Capital expenditure | $454,000 | $256,000 | $1.31M | $5.75M | $5.55M |
| Total debt | $3.59M | $3.99M | $4.74M | $5.41M | $4.41M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics EWTX | $4.89B | +28% | n/a | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | $1.88B | -11% | -20% | -3% | 1.1× | 11.9% |
| Cytokinetics CYTK | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a |
| BridgeBio Pharma BBIO | $14.5B | +10% | +167% | -37% | 18.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EWTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.8% | +2.1% | 2nd highest of 21 |
| 6-month return | +27.5% | -1.2% | 7th highest of 21 |
| Distance from 52-week high | -7.2% | -24.0% | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 5.4× | 28.4% | +16.4% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |